These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine. Bienek DR; Chang CK; Cohen ME Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265 [TBL] [Abstract][Full Text] [Related]
25. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses. Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249 [TBL] [Abstract][Full Text] [Related]
26. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants. Klinman DM; Klaschik S; Tomaru K; Shirota H; Tross D; Ikeuchi H Vaccine; 2010 Feb; 28(8):1919-23. PubMed ID: 20188247 [TBL] [Abstract][Full Text] [Related]
27. Potentiation of an anthrax DNA vaccine with electroporation. Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850 [TBL] [Abstract][Full Text] [Related]
28. Development of an in vitro-based potency assay for anthrax vaccine. Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620 [TBL] [Abstract][Full Text] [Related]
30. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)). Hannesschlager JR Vaccine; 2007 Apr; 25(17):3247. PubMed ID: 17234308 [No Abstract] [Full Text] [Related]
31. Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Ribot WJ; Powell BS; Ivins BE; Little SF; Johnson WM; Hoover TA; Norris SL; Adamovicz JJ; Friedlander AM; Andrews GP Vaccine; 2006 Apr; 24(17):3469-76. PubMed ID: 16519970 [TBL] [Abstract][Full Text] [Related]
32. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302 [TBL] [Abstract][Full Text] [Related]
33. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Klinman DM; Currie D; Lee G; Grippe V; Merkel T Microbes Infect; 2007 Oct; 9(12-13):1478-83. PubMed ID: 17913545 [TBL] [Abstract][Full Text] [Related]
34. [Progress on the vaccine for anthrax]. Zhan DW; Wang P; Wang LC; Zhang ZS Wei Sheng Wu Xue Bao; 2005 Feb; 45(1):149-52. PubMed ID: 15847185 [TBL] [Abstract][Full Text] [Related]
35. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Hepler RW; Kelly R; McNeely TB; Fan H; Losada MC; George HA; Woods A; Cope LD; Bansal A; Cook JC; Zang G; Cohen SL; Wei X; Keller PM; Leffel E; Joyce JG; Pitt L; Schultz LD; Jansen KU; Kurtz M Vaccine; 2006 Mar; 24(10):1501-14. PubMed ID: 16271808 [TBL] [Abstract][Full Text] [Related]